Burning Rock Biotech Limited reiterated revenue guidance for the full year 2023. For the period, the company expects revenue guidance of approximately 20% growth over 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.15 USD | -5.30% | -5.55% | -23.12% |
1st Jan change | Capi. | |
---|---|---|
-23.12% | 73.35M | |
-24.16% | 7.66B | |
+69.34% | 4.35B | |
-3.15% | 2.53B | |
-44.99% | 2.21B | |
-13.44% | 1.79B | |
-21.62% | 1.48B | |
+14.43% | 1.18B | |
-44.31% | 1.13B | |
+19.88% | 997M |
- Stock Market
- Equities
- BNR Stock
- News Burning Rock Biotech Limited
- Burning Rock Biotech Limited Reiterates Revenue Guidance for the Full Year 2023